S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Guggenheim lowered its price target on Tenax Therapeutics (NASDAQ:TENX) to $14.00 from $15.00 on Thursday, while maintaining a Buy rating on the stock. The new target still represents significant upside from the current trading price of $5.91, with analyst targets ranging from $10.40 to $30.00 for the $234.58 million market cap company.
The adjustment follows Tenax’s second-quarter 2025 earnings report, which revealed a delay in the company’s LEVEL clinical trial timeline. Tenax now expects to complete enrollment of 230 patients for the LEVEL trial in the first half of 2026, pushed back from the previous target of year-end 2025. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 40.48, providing ample resources for trial completion.
The company also updated its timeline for top-line data, which is now expected in the second half of 2026 rather than mid-2026 as previously projected. Despite these delays, Tenax reported high rates of study and therapy continuation during both the blinded and open-label extension stages of the trial.
Tenax’s second Phase 3 trial, LEVEL-2, remains on schedule to begin this year. The company has completed qualification visits at over 85 new sites across 15 additional countries for this global study.
Guggenheim’s revised price target reflects updated launch timing assumptions, though the firm continues to view the Phase 3 LEVEL readout in the second half of 2026 as a major catalyst for the stock. According to InvestingPro, the company holds more cash than debt, though analysts expect profitability challenges this year. Get access to 8 more exclusive InvestingPro Tips for deeper insights into Tenax’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.